- Verizon joins the busy virtual care market with the launch of its new Verizon BlueJeans telemedicine platform on Monday, building on continued demand for virtual care after COVID-19.
- The company redesigned the video conferencing platform it acquired last year for health and life sciences clients. BlueJeans aims to provide a streamlined facility and streamlined user experience for its clients by addressing two key challenges for telemedicine providers: technology savvy and visitation efficiency, the New York-based telecommunications giant said.
- Tami Erwin, CEO of Verizon Business, said in a statement Monday that Verizon’s beginning in the telemedicine industry is “just the beginning,” “especially when you consider that the innovation resulting from 5G mobility, capabilities of broadband, and the cloud will result.” BlueJeans Telehealth will generally be available in May.
Hospitals and medical practices were slow to offer telemedicine to their existing patients before the coronavirus hit the United States early last year and received little to no reimbursement, among other things. Over the past year, COVID-19 has radically accelerated the need for a digital pathway to care, as providers have tried to personally recover lost volume and monitor their patients at home.
However, some providers, particularly small and resource-intensive facilities, have reported problems with costs or efforts to implement new telemedicine solutions.
BlueJeans aims to improve some of these issues by simplifying the setup and user experience for its vendor customers. Erwin said Verizon worked with an advisory board of physicians and healthcare executives to build the BlueJeans telemedicine platform to ensure it was quick and easy to use even for those new to virtual care.
The vast majority of healthcare organizations – 81% – expect more investment in telemedicine in the next two to three years, according to Verizon research, while 85% of decision-makers said ease of use is one of the top five drivers of product production. Result of virtual media.
Verizon bought BlueJeans for $ 400 million a year ago to enter the unified communications market. The company, which sees its Verizon Business B2B division as a growth area, plans to add the platform to its 5G product roadmap for its customers.
BlueJeans offers one-click access to its platform on a mobile device or desktop computer with no downloads required. The homepage is provider-friendly and includes onboard patients, initial medical surveys, and training materials. The platform provides patients with medical interpretation services in more than 200 languages, including sign language.
According to Verizon, the platform integrates existing EHR workflows. BlueJeans partnered with EHR giant Epic in October to respond to customer requests. However, a Healthcare Dive spokesperson clarified that BlueJeans is not currently included in Epic EHR, although many notes are in the works and expected to be released soon.
The company declined to share a specific number, but BlueJeans ’current life sciences and health clients include Philadelphia Children’s Hospital, NHS Guy and the St Thomas Foundation Trust, Amicus Therapeutics, University of Louisville Medical School, Penn Medicine, and the Central NHS Healthcare Trust Community of London
The license is based on a per-visit model to simplify the refund process. However, BlueJeans licenses are available in a named host format, the spokesperson said.
Many technology companies are trying to break snowball market share by partnering or varying offers to compete with telemedical giants like Teladoc Health. In particular, Amazon is introducing its own virtual support network from this summer, which will be sold to employers nationwide.
Despite growing competition in the field as companies seek unprecedented funding for digital health, market observers say there is plenty of room for new entrants to the market. Up to $ 250 billion in health care spending could be digitized over time, according to research at McKinsey. In comparison, before the pandemic, the combined annual revenue of U.S. tele-pharma companies was estimated at only $ 3 billion.